Skip to content

Emerging Drugs and Targets for Alzheimer's Disease: Neuronal Plasticity,
Stock Photo: Cover May Be Different

Emerging Drugs and Targets for Alzheimer's Disease: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies Hardcover - 2010

by Martinez, A. (ed)

  • Used
  • Hardcover

Description

Royal Society Of Chemistry, 2010. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In good all round condition. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,700grams, ISBN:9781849730648
Used: See description
NZ$36.14
NZ$26.78 Shipping to USA
Standard delivery: 7 to 20 days
More Shipping Options
Ships from Anybook.com (Lincolnshire, United Kingdom)
The BIBLIO Guarantee | Ask Seller a Question

Details

  • Title Emerging Drugs and Targets for Alzheimer's Disease: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies
  • Author Martinez, A. (ed)
  • Binding Hardcover
  • Edition Us Edition
  • Pages 326
  • Volumes 1
  • Language ENG
  • Publisher Royal Society Of Chemistry, Cambridge, England
  • Date 2010
  • Features Bibliography, Index, Table of Contents
  • Bookseller's Inventory # 9391002
  • ISBN 9781849730648 / 1849730644
  • Weight 1.36 lbs (0.62 kg)
  • Dimensions 9.2 x 6.2 x 1 in (23.37 x 15.75 x 2.54 cm)
  • Dewey Decimal Code 616.831

About Anybook.com Lincolnshire, United Kingdom

Biblio member since 2004
Seller rating: This seller has earned a 5 of 5 Stars rating from Biblio customers.

Established in 1998 Anybook.com. has sold millions of scholastic books to university libraries, academics, students and reflective bibliophiles throughout the world. As the majority of our books are ex-library they are well bound, in good, clean condition and ideally suited for study and research. Our books cover a huge range of academic disciplines from Mathematics, Science and Philosophy to Art and Literature as well as many works in other European languages.

Terms of Sale:

Based in central Lincoln, Anybook.com. sells exclusively online. We specialise in academic works. All our books are in good condition or better, unless otherwise described. We will respond to your enquiry promptly and mail books out within 1 working day. We use reputable couriers at greatly discounted postage rates. As well as Visa and Mastercard, we also accept Switch, Discover and Solo. We also accept Paypal (www.paypal.com) payments. Other methods of payment are possible but please email us for details. Remember if you are unsatisfied in any way with any purchase, we will give you a complete and unconditional refund. E-mail us if you have any questions about the service we offer. Please be aware our prices and shipping costs do not include local import taxes which may need to be paid by the customer upon receipt.

Browse books from Anybook.com

From the rear cover

Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective therapeutic intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts these books will be an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the drugs for neurodegeneration field.

Categories

About the author

Ana Martinez obtained her PhD in Organic Chemistry from the Complutense University of Madrid before becoming a researcher at the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). Since 1995, her interests have focused on neurodegenerative disorders and she has led numerous research projects on the medicinal chemistry and rational drug design with the aim of finding new treatments for Alzheimer's disease. In February 2002, she joined NeuroPharma (now NOSCIRA) as R&D Director where she led projects from the discovery of potential new therapies to the final proof of concept in animal models. In February 2008, she returned to her academic position at the Medicinal Chemistry Institute (CSIC) leading several projects on neurodegenerative disease therapies and acting as an external scientific advisor to a number of pharmaceutical companies. Her main areas of research currently involve GSK-3 inhibitors and dual binding site acetylcholinesterase inhibitors. She has authored over a hundred and fifty scientific publications and has more than twenty active patents in the field.

Hang on… we’re fetching the requested page.